Dermaxon
  • Home
  • About Us
    • Contact
  • News
  • Science
  • Our Technologies
    • The human brain
    • Skin
    • Pain
  • Pipeline
Select Page

Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders

Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders – PMC (nih.gov)

  • Facebook
  • RSS

Copyright, Dermaxon. All rights reserved.